

# Susan Guy

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9528915/susan-guy-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10  
papers

47  
citations

3  
h-index

6  
g-index

10  
ext. papers

64  
ext. citations

3.3  
avg, IF

1.81  
L-index

#	Paper	IF	Citations
10	Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban. <i>International Journal of Laboratory Hematology</i> , <b>2015</b> , 37, 834-43	2.5	14
9	The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , <b>2008</b> , 142, 466-8	4.5	13
8	Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 594-597	4.5	6
7	Argatroban is stable in citrated whole blood for 24 hours. <i>International Journal of Laboratory Hematology</i> , <b>2018</b> , 40, 484-487	2.5	3
6	A cost-effective approach to factor assay calibration using a truncated live calibration curve. <i>International Journal of Laboratory Hematology</i> , <b>2019</b> , 41, 679-683	2.5	3
5	Von Willebrand factor activity assay errors. <i>Haemophilia</i> , <b>2016</b> , 22, e74-6	3.3	3
4	More on the Limitations of the Activated Partial Thromboplastin Time for Monitoring Argatroban Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2017</b> , 43, 642-643	5.3	2
3	Laboratory methods for monitoring argatroban in heparin-induced thrombocytopenia. <i>International Journal of Laboratory Hematology</i> , <b>2021</b> ,	2.5	1
2	Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT).. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2021</b> , 27, 10760296211066945	3.3	1
1	Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A. <i>Haemophilia</i> , <b>2020</b> , 26, 1181-1186	3.3	1